Physician profile
Rajan Goyal
NPI 1063695658
$12,237.34
in general payments reported to CMS, 2019-2025
47 companies · $2,596 in 2025
The $2,596 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,362 · 2020: $1,332 · 2021: $1,491 · 2022: $1,297 · 2023: $1,525 · 2024: $1,635 · 2025: $2,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,068 · Education: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,067.55 |
| Education | $687.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,638.10 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,666.54 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,147.57 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Astellas Pharma US INC | $928.86 | 2019-2025 | Cresemba |
| Actelion Pharmaceuticals US, INC. | $815.75 | 2019-2025 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $448.35 | 2019-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $310.21 | 2019-2025 | |
| Grifols USA, LLC | $296.79 | 2019-2025 | Prolastin-C Liquid |
| Novo Nordisk INC | $274.71 | 2019-2023 | Rybelsus, Ozempic |
| United Therapeutics Corporation | $271.01 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Philips North America LLC | $264.57 | 2019-2020 | |
| Pulmonx Corporation | $237.04 | 2019-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Verona Pharma, INC. | $232.14 | 2025 | Ohtuvayre |
| Amgen INC. | $217.90 | 2024-2025 | Tezspire |
| Genzyme Corporation | $194.34 | 2019-2025 |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajan Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.